Kite Pharma

Kite sails into in vivo CAR-T space via $350M Interius buyout

Gilead has become the latest pharma to strengthen its in vivo credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics.

James Waldron Aug 21, 2025 9:59am

Businessman about to be crushed by falling dominos

Fierce Pharma

BioNTech to wind down cell therapy manufacturing in Maryland

Jun 18, 2025 10:23am

ASCO: Kite's CAR-T flies high in phase 1 B-cell lymphoma study

May 31, 2025 7:00pm

Gilead to lay off 72 staffers, shutter Seattle R&D office

Nov 14, 2024 1:09pm

ASH: Gilead-Arcellx data build CAR-T's case in advanced myeloma

Nov 5, 2024 3:08pm

Professional kite surfer soars through the air

2 Kite vets fly over to Kyverna Therapeutics—Chutes & Ladders

Sep 20, 2024 8:30am